🇺🇸 FDA
Pipeline program

Umbralisib

TG-UPCC-108

Phase 2 small_molecule completed

Quick answer

Umbralisib for Chronic Lymphocytic Leukemia is a Phase 2 program (small_molecule) at TG THERAPEUTICS, INC. with 4 ClinicalTrials.gov record(s).

Program details

Company
TG THERAPEUTICS, INC.
Indication
Chronic Lymphocytic Leukemia
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials